Home > Oncology > ASCO 2022 > SKYSCRAPER-02: additional tiragolumab does not help patients with untreated SCLC

SKYSCRAPER-02: additional tiragolumab does not help patients with untreated SCLC

Presented By
Dr Charles Rudin, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ASCO 2022
Trial
Phase 3, SKYSCRAPER-02
Tiragolumab, added to atezolizumab, carboplatin, and etoposide, did not improve the progression-free survival (PFS) or overall survival (OS) of patients with untreated extensive-stage small-cell lung cancer (SCLC), as was shown by the primary results of the phase 3 SKYSCRAPER-02 trial. Tiragolumab is a human anti-TIGIT monoclonal antibody under investigation in several cancer settings, such as non-SCLC and oesophageal cancer. Dr Charles Rudin (Memorial Sloan Kettering Cancer Center, NY, USA) aimed to assess the efficacy of tiragolumab in addition to the standard-of-care (atezolizumab plus carboplatin and etoposide) for patients with extensive-stage SCLC in the SKYSCRAPER-02 trial (NCT04256421) [1,2]. Patients were randomised 1:1 to additional tiragolumab (n=243) or placebo (n=247). PFS was the primary endpoint of the study. The primary endpoint was not met i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on